News & Events
Crinetics Pharmaceuticals to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
Event Date: September 4, 2024
READ MORECrinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Crinetics management will participate in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global...
READ MORECrinetics Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 103,900 shares of its common stock to fifteen new...
READ MORECrinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8
Event Date: August 8, 2024
READ MORECrinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reported second quarter 2024 financial and provided a business update on clinical progress.
READ MORECrinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
Crinetics launches ACRO/TRUTH, a website and educational initiative aimed at highlighting the various acromegaly treatment challenges.
READ MORECrinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
Event Date: Crinetics Pharmaceuticals announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, after the close of the U.S. financial markets.
READ MORECrinetics Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 137,900 shares of its common stock to eighteen new...
READ MOREEY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
Ernst & Young LLP announces that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, was named an Entrepreneur...
READ MORECrinetics Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 158,000 shares of its common stock to nine new...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
